Ghulam J. Mufti

TL;DR: Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome and the safety profile was consistent with previous reports.

TL;DR: It is demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q) and could indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.

TL;DR: Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event.

TL;DR: It is indicated that MDS progression arises through multiple hits that alter levels of CD34(+) cell apoptosis and proliferation and is inversely correlated with both International Prognostic Scoring System score and cytogenetic risk group; highest levels observed in patients with low score and/or good risk cytogenetics.